Homology Medicines, Inc. (FIXX): Price and Financial Metrics

Homology Medicines, Inc. (FIXX): $16.82

0.13 (+0.77%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

D

FIXX Price/Volume Stats

Current price $16.82 52-week high $17.51
Prev. close $0.93 52-week low $0.46
Day low $16.20 Volume 22,300
Day high $17.51 Avg. volume 390,307
50-day MA $0.78 Dividend yield N/A
200-day MA $0.91 Market Cap 978.08M

FIXX Stock Price Chart Interactive Chart >


Homology Medicines, Inc. (FIXX) Company Bio


Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities—gene editing and gene therapy. The company was founded in 2015 and is based in Bedford, Massachusetts.


FIXX Latest News Stream


Event/Time News Detail
Loading, please wait...

FIXX Latest Social Stream


Loading social stream, please wait...

View Full FIXX Social Stream

FIXX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Continue Researching FIXX

Want to see what other sources are saying about Homology Medicines Inc's financials and stock price? Try the links below:

Homology Medicines Inc (FIXX) Stock Price | Nasdaq
Homology Medicines Inc (FIXX) Stock Quote, History and News - Yahoo Finance
Homology Medicines Inc (FIXX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!